ORPHA:180247
Vaginal carcinoma
Also known as: Vaginal malignant epithelial tumor
Publications
3,375
90th percentile
Trials
16
Interventional, condition-specific
Researchers
1,236
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A group of rare vaginal tumors comprising HPV-associated and HPV-independent squamous cell carcinoma, glandular tumors (including HPV-associated adenocarcinoma, endometrioid carcinoma, clear cell carcinoma, gastric type and intestinal type mucinous carcinoma, and mesonephric adenocarcinoma), adenocarcinoma of Skene gland origin, adenosquamous carcinoma, and adenoid basal carcinoma. Depending on the type of tumor and disease stage, patients may present with symptoms related to a vaginal mass, vaginal bleeding and/or discharge, postcoital bleeding, urinary symptoms, pelvic pain, and a foreign body sensation within the vagina.
How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0015867
- UMLS:C0262659
- NCIT:C3917
Additional Mondo synonyms (4)
carcinoma of the vagina · carcinoma of vagina · vagina carcinoma · vaginal carcinoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
3,375 matched papers (1,741 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
16 matched on ClinicalTrials.gov (5 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
6
Drugs / clinical candidates · MONDO_0015867
- CYCLOSPORINE·phase 2
- FLUDARABINE PHOSPHATE·phase 2
- IPILIMUMAB·phase 2
- MYCOPHENOLATE MOFETIL·phase 2
- NIVOLUMAB·phase 2
- TALAZOPARIB·phase 1
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
3,375
3,375 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
3,375 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
1,741 in the last 10 years · high confidence · 90th percentile (publications denominator)
Phrase hits: 3,375 · MeSH hits: 0
Who's working on it?
1,236
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Liu Y7 papers · 2026
Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery (Fudan University), Shanghai 201203, China. Electronic address: liuyu@fudan.edu.cn.
Papers in Europe PMC - 02Li J6 papers · 2026
School of Optical Electrical and Computer Engineering, University of Shanghai for Science and Technology, Shanghai, China.
Papers in Europe PMC - 03Zhang H5 papers · 2026
Department of Gynecology, Linyi People's Hospital, Linyi, 276000, Shandong Province, China. Electronic address: 13864999757@163.com.
Papers in Europe PMC - 04Li R4 papers · 2026
Department of Obstetrics and Gynecology, Peking University Shenzhen Hospital, Shenzhen, China. lrz6666@126.com.
Papers in Europe PMC - 05Li X4 papers · 2026
Department of Gynecology, The First Affiliated Hospital of Bengbu Medical College, No.287, Changhuai Road, Bengbu, Anhui Province 233000, China.
Papers in Europe PMC - 06Wang J4 papers · 2025
Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery (Fudan University), Shanghai 201203, China. Electronic address: 20111030011@fudan.edu.cn.
Papers in Europe PMC - 07Wang X4 papers · 2026
Department of Urology, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Papers in Europe PMC - 08Li C3 papers · 2025
Department of Obstetrics and Gynecology, The Second Hospital of Anhui Medical University, No. 678 Furong Road, Hefei, Anhui 230601, China.
Papers in Europe PMC - 09Li M3 papers · 2026
Department of Gynecology and Obstetrics, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
Papers in Europe PMC - 10Li Y3 papers · 2026
Department of Urology, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
16
interventional trials for this specific condition
16 interventional trials matched this specific condition name; 5 currently recruiting in our sample.
Data as of 11 September 2026
16 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 94.2th percentile).
high confidence · 94.2th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
16 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07407647·RECRUITING·Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer
Not reviewed·Conditions: Anal Carcinoma · Cervical Carcinoma · Malignant Female Reproductive System Neoplasm · Rectal Carcinoma·Matched via name phrase
- NCT03968406·RECRUITING·Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
Not reviewed·Conditions: Malignant Female Reproductive System Neoplasm · Recurrent Cervical Carcinoma · Recurrent Endometrial Carcinoma · Recurrent Fallopian Tube Carcinoma·Matched via name phrase
- NCT06686043·RECRUITING·HPV Vaccine, Imiquimod, and Metformin Combination Trial
Not reviewed·Conditions: Cervical Carcinoma · Vaginal Carcinoma · Vulvar Carcinoma · HPV (Human Papillomavirus)-Associated Carcinoma·Matched via name phrase
- NCT05952947·RECRUITING·HRYZ-T101 Injection for HPV18 Positive Solid Tumor
Not reviewed·Conditions: Cervical Cancer · Head and Neck Squamous Cell Carcinoma · Carcinoma of Vagina · Carcinoma of Penis·Matched via name phrase
- NCT05969860·RECRUITING·At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Not reviewed·Conditions: Advanced Anal Carcinoma · Advanced Biliary Tract Carcinoma · Advanced Bladder Carcinoma · Advanced Breast Carcinoma·Matched via name phrase
Observational and natural-history studies
3 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 44 · after dedupe 44 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 44 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (44)
- ctis·2024-514920-18-00·Cancelled·ABIMMUNE: A Phase I/II study evaluating the safety and clinical activity of anti-PDL1 (Durvalumab [MEDI4736]) + Anti CTLA-4 (Tremelimumab) antibodies administrated in combination with stereotactic body radiotherapy (SBRT) in patients with metastatic squamous cell carcinoma of head and neck, lung, oesophageus, cervix, vagina, vulva or anus.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN18283468·No longer recruiting·A clinical trial to learn more about the absorption of radiolabeled drug LXE408, how the body breaks it down, and how quickly the body gets rid of it in healthy men
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12164818·Recruiting·Validation study for the WID-qEC test in women undergoing hysterectomy: A diagnostic accuracy study
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN79155276·No longer recruiting·A study to learn if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12434145·Recruiting·A first in human study to investigate the safety and tolerability of CV6-168 in combination with anti-cancer treatments in patients with advanced cancer.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12057804·Recruiting·A study of nipocalimab in pregnancies for severe hemolytic disease of the fetus and newborn (HDFN)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16482972·No longer recruiting·A Phase I, non-randomized, open-label, crossover study designed to evaluate the pharmacokinetic profile of iptacopan (LNP023) following single-dose administration of iptacopan modified-release formulations in comparison to a reference capsule formulation in healthy participants
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11896599·Recruiting·Does the timing and order of breast surgery and hormone treatment affect the quality of life and the amount of surgery required in post-menopausal women with breast cancer? The EndoNET study
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN60385283·No longer recruiting·A study to investigate the safety, tolerability, and potential effect of RXC007 in patients with idiopathic pulmonary fibrosis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN89539429·No longer recruiting·A trial of hormone therapy and abemaciclib for early breast cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN99049821·No longer recruiting·A clinical trial to evaluate the efficacy and safety of Shufeng Jiedu capsule in acute exacerbation of chronic obstructive pulmonary disease (COPD)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN79334891·No longer recruiting·Hydroxychloroquine in ANCA Vasculitis Evaluation (HAVEN)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11264442·Suspended·NEO21-RS: A prospective study of the outcomes following 21-gene recurrence score directed neoadjuvant therapy in ER-positive, HER2-negative breast cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN44453201·No longer recruiting·Will HIV-positive individuals who have drug resistance and have suppressed amount of virus in the blood on protease inhibitor regimen still remain suppressed if switched to a regimen containing bictegravir, emtricitabine and tenofovir alafenamide?
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12196200·No longer recruiting·Can we use estrogen-containing therapy to improve pain in women after menopause with hand osteoarthritis? (HOPE-e study)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN23662758·No longer recruiting·A trial looking at progesterone to treat early breast cancer in premenopausal women
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN78807934·No longer recruiting·Clinical trial with fermented milk drink on functional constipation
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN76291951·No longer recruiting·WISTERIA: WEE1 inhibitor with cisplatin and radiotherapy
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12213700·No longer recruiting·A study to assess the effects of enobosarm on early breast cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12509361·No longer recruiting·BRAVO Study: Surgery vs. Immunotherapy – Which treatment is best in bladder cancer?
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11659025·No longer recruiting·PORTEC-4a: Randomised trial of standard or molecular profile-based recommendation for radiotherapy after surgery for women with early stage endometrial cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13364447·No longer recruiting·Stitch, progesterone or pessary: a randomised controlled trial
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN31243262·No longer recruiting·Evaluating the biological and clinical effects of the combination of palbociclib with letrozole as neoadjuvant therapy in post-menopausal women with primary breast cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN48776874·No longer recruiting·Evaluation of a new self applied treatment for early stage pre cancerous disease of the cervix
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN45751386·No longer recruiting·Trial of treatment and follow-up of vaginal intraepithelial neoplasia (VAIN)
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Vaginal carcinoma — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Vaginal carcinoma" OR "Vaginal malignant epithelial tumor" OR "carcinoma of the vagina" OR "carcinoma of vagina" OR "vagina carcinoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Vaginal carcinoma" OR "Vaginal malignant epithelial tumor" OR "carcinoma of the vagina" OR "carcinoma of vagina" OR "vagina carcinoma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 16 interventional · 3 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T09:04:39.694Z
